Outpatient Treatment for Small-Cell Lung Cancer
Author Information
Author(s): H Gogas, FJ Lofts, TRJ Evans, FJC Millard, R Wilson, JL Mansi
Primary Institution: St George's Hospital, London
Hypothesis
To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC).
Conclusion
Epirubicin and etoposide is an active and well-tolerated outpatient regimen for treating SCLC, although survival data were disappointing.
Supporting Evidence
- Overall response rate was 64.4%, with 23.7% complete responses.
- Median survival was 10.5 months for limited disease and 7 months for extensive disease.
- 79% of patients with shortness of breath reported symptom improvement.
Takeaway
Doctors gave medicine to help people with a type of lung cancer, and many felt better, but not everyone lived longer.
Methodology
Patients received epirubicin and etoposide at specified doses for a maximum of six cycles, with evaluations for response and toxicity.
Potential Biases
The results may be affected by the inclusion of unselected patients with varying health statuses.
Limitations
The study included patients with poor prognostic features and did not universally apply thoracic irradiation.
Participant Demographics
Median age was 64 years, with a male-female ratio of 42:28, and 50% had metastatic disease.
Statistical Information
P-Value
0.02
Confidence Interval
CI 52-76.8%
Statistical Significance
p=0.02
Want to read the original?
Access the complete publication on the publisher's website